Evidence map›Paper›PMID 24496803›Full record

ArticleDiabetes care2014

Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas.

Ronac Mamtani, Nick Pfanzelter, Kevin Haynes, Brian S Finkelman, Xingmei Wang, Stephen M Keefe, Naomi B Haas, David J Vaughn, James D Lewis

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes care, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 3 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Metformin: A Novel Weapon Against Inflammation.Frontiers in pharmacology · 2021
    Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Ronac MamtaniAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA ronac.mamtani@uphs.upenn.edu.
Nick PfanzelterAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Kevin HaynesCenter for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA.
Brian S FinkelmanCenter for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA.
Xingmei WangCenter for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA.
Stephen M KeefeAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Naomi B HaasAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
David J VaughnAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
James D LewisCenter for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA.
University of Pennsylvania · US

Funding

INSTITUTIONAL CLINICAL AND TRANSLATIONAL SCIENCE AWARDUL1RR024134 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2006 to 2011
$70.4M
Physician Scientist Training in Clinical OncologyK12CA076931 · NCI · UNIVERSITY OF PENNSYLVANIA · PI STEPHEN Patrick HUNGER, LYNN M. SCHUCHTER · 1997 to 2026
$16.5M
Test-Treat strategy to prevent ulcerative colitis relapseK24DK078228 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI LEWIS, JAMES D · 2007 to 2016
$1.9M
Clinical and Genetic Predictors of Unstable Warfarin ResponseF30HL115992 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI FINKELMAN, BRIAN · 2012 to 2014
$100k
NCI NIH HHS K12 CA076931NCI NIH HHS K12-CA-076931NCRR NIH HHS UL1 RR024134NCRR NIH HHS UL1-RR-024134NHLBI NIH HHS 1F30-HL-115992-01NHLBI NIH HHS F30 HL115992NIDDK NIH HHS K24 DK078228NIDDK NIH HHS K24-DK-078228
6 · The paper itself

Abstract

objectivePrevious studies evaluating the effect of metformin on cancer risk have been impacted by time-related biases. To avoid these biases, we examined the incidence of bladder cancer in new users of metformin and sulfonylureas (SUs). RESEARCH DESIGN AND

methodsThis cohort study included 87,600 patients with type 2 diabetes in The Health Improvement Network database. Use of metformin or an SU was treated as a time-dependent variable. Cox regression-generated hazard ratios (HRs) compared metformin use with SU use, adjusted for age, sex, smoking, obesity, and HbA1c level.

resultsWe identified 196 incident bladder cancers in the metformin cohort and 66 cancers in the SU cohort. Use of metformin was not associated with decreased bladder cancer risk (HR 0.81 [95% CI 0.60-1.09]). This association did not differ by sex (P for interaction = 0.20). We observed no association with duration of metformin relative to SU use (3 to <4 years of use: 0.57 [0.25-1.34]; 4 to <5 years of use: 0.93 [0.30-2.85; ≥5 years of use: 1.18 [0.44-3.19]; P for trend = 0.26).

conclusionsUse of metformin is not associated with a decreased incidence of bladder cancer. Similar methods should be used to study other cancers that have previously been identified as potentially preventable with metformin.

Indexed as

AgedCohort StudiesDatabases, FactualDiabetes Mellitus, Type 2FemaleFollow-Up StudiesHumansHypoglycemic AgentsIncidenceMaleMetforminMiddle AgedNeoplasmsRetrospective StudiesSulfonylurea CompoundsUrinary Bladder NeoplasmsHypoglycemic AgentsMetforminSulfonylurea Compounds

Identifiers

PMID24496803
PMCPMC4067396
OpenAlexW2151190595

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.